Abstract:Background Natural killer (NK) cells have potent antitumor activities. Nevertheless, adoptive transfer therapy of NK cells has gained very limited success in patients with solid tumors as most infused NK cells remain circulating in the peripheral blood instead of entering tumor sites. Chemokines and their receptors play important roles in NK cell distribution. Enhancing chemokine receptors on immune cells to match and be driven to tumor-specific chemokines may improve the therapeutic efficacy of NK cells. Methods The CCR5-CCL5 axis is critical in NK cell homing to tumor sites. Thus, we analyzed CCR5 expression on NK cells from patients with cancer and healthy donors. We then upregulated CCR5 and CCL5 with lentiviruses and oncolytic viruses in NK and tumor cells, respectively. Animal experiments were also carried out to test the efficacy of the combination of oncolytic virus with NK cells. Results In NK cells from patients with various solid tumors or healthy subjects, CCR5 was expressed at low levels before and after expansion in vitro. CCR5-engineered NK cells showed enhanced tumor infiltration and antitumor effects, but no complete regressions were noted in the in vivo tumor models. To further improve therapeutic efficacy, we constructed CCL5-expressing oncolytic vaccinia virus. In vitro data demonstrated that vaccinia virus can produce CCL5 in tumor cells while infectivity remained unaffected. Supernatants from tumor cells infected by CCL5-modified vaccinia virus enhanced the directional movement of CCR5-overexpressed NK cells but not green fluorescent protein (GFP)-expressing cells. More importantly, NK cells were resistant to the vaccinia virus and their functions were not affected after being in contact. In vivo assays demonstrated that CCL5-expressing vaccinia virus induced a greater accumulation of NK cells within tumor lesions compared with that of the prototype virus. Conclusion Enhancement of matched chemokines and chemokine receptors is a promising method of increasing NK cell homing and therapeutic effects. Oncolytic vaccinia viruses that express specific chemokines can synergistically augment the efficacies of NK cell-based therapy.

NK Cells Are Migrated and Indispensable in the Anti-Tumor Activity Induced by CCL27 Gene Therapy

Antitumor Effect By Interleukin-11 Receptor Alpha-Locus Chemokine/Ccl27, Introduced Into Tumor Cells Through A Recombinant Adenovirus Vector

Overexpressed Cxcr4 And Ccr7 On The Surface Of Nk92 Cell Have Improved Migration And Anti-Tumor Activity In Human Colon Tumor Model

Cotransduction of CCL27 Gene Can Improve the Efficacy and Safety of IL-12 Gene Therapy for Cancer.

C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models

Cytokine Gene Therapy Using Adenovirally Transduced, Tumor-Seeking Activated Natural Killer Cells.

Intratumoral Delivery of CCL25 Enhances Immunotherapy Against Triple-Negative Breast Cancer by Recruiting CCR9+ T Cells

IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors

Augmented Anti-Tumor Activity of NK-92 Cells Expressing Chimeric Receptors of TGF-βR II and NKG2D

Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence

Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy.

Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas

Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency

Targeting Natural Killer Cells for Tumor Immunotherapy

Induction of antitumor immunity by CCR2 transduced CD8+TILs in mouse lung carcinoma

CCL3 augment antitumor immune priming in the tumor draining lymph node

The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control